International Journal of Translational Science

From Promise to Practice A HEALinc Global Summit White Paper

Desirée C. T. Cox — 2026-10-15

This paper, developed by HEALinc CEO and Founder Dr. Desirée Cox, translates a day of multidisciplinary discussion at the 2026 HEALinc Global Summit, New York City (NYC) Day Conclave into a coherent systems framework and action agenda. It is not a transcript, clinical guideline, regulatory opinion, or endorsement of every intervention or claim discussed at the Summit.

The source material captures perspectives from scientists, physicians, biotechnology leaders, lawyers, investors, former regulators, patient advocates, educators, architects, and other participants. Sponsors, speakers, and key opinion leaders represented at the HEALinc New York City (NYC) Day Conclave are identified in the Appendices. The proceedings ranged from late-stage clinical development and international regulatory pathways to whole-person health, patient experience, digital monitoring, medical education, and the design of healing environments. The purpose of this paper is to identify the recurring system-level insights, clarify where genuine convergence occurred, and convert those insights into a practical architecture for translation.

Some interventions and outcomes described during the discussions were preliminary, anecdotal, contested, or outside established standards of evidence. They are treated here as signals of emerging questions and unmet needs – not as validated clinical conclusions. Any therapy must be evaluated according to its own evidence, manufacturing quality, ethical acceptability, regulatory status, and risk profile.

Interpretive Stance
The field should neither equate regulatory caution with obstruction nor equate permissive access with progress. The task is to create controlled velocity: faster, more coherent learning and access under stronger evidence, ethics, quality, and accountability.

Wisdom as Infrastructure: A New Architecture for Longevity and Regeneration

Desirée C. T. Cox — 2026-10-15

Longevity science and regenerative medicine have moved the limits of translational medicine. The sciences of aging and age-related diseases, cell and gene therapies, biomaterials, digital phenotyping, and artificial intelligence are expanding what can be measured and modified across the life course. Yet the field’s decisive bottleneck may no longer be discovery alone. Technical capacity is advancing faster than the institutional capacity to decide what should count as progress, how uncertainty should be governed, and how biological gains become durable and equitably distributed human benefit.

This perspective advances the proposition that wisdom is infrastructure. Wisdom is defined here not as intuition or individual authority, but as the organized capacity to integrate heterogeneous evidence, deliberate explicitly about values, anticipate consequences across time, and implement innovation with the people and systems it will affect.

The perspective situates this proposition within a broader architecture of human flourishing and proposes a translational human flourishing framework comprising six integrative and interdependent domains: biological integrity and plasticity; functional capacity and resilience; agency, purpose, and meaning; social connection and participation; enabling environments; and ethical governance and equity.

The framework does not displace mechanistic, disease-specific, or regulatory endpoints. It connects them to the full causal pathway through which an intervention becomes meaningful in a human life. A research agenda is proposed around multidomain outcomes, longitudinal trajectories, implementation and equity, governance indicators, learning health systems, and place-based translational ecosystems.

The central claim is deliberately ambitious but empirically bounded: longevity and regenerative medicine will fulfill their promise only when the infrastructures that accelerate innovation are matched by infrastructures that give innovation direction, legitimacy, memory, and human purpose.

Advancing Future Health Through Responsible Global Access

Desirée C. T. Cox — 2026-10-15

Established in 2018, the HEALinc Global Summit is an international gath- ering dedicated to advancing the frontiers of future health and expanding global access to advanced longevity and regenerative therapies that support a proactive approach to whole-person health. Spanning Latin America and the Caribbean, the United States, Europe, Africa, the Middle East, and Asia, the three-day Summit brings together visionaries, scientists, and entrepreneurs committed to transforming health and extending human potential.

Combining Senolytic, Stem Cell, and NAD+ Strategies as an Integrated Protocol

Gregory Kelly — 2026-10-15

Human life expectancy has risen faster than the span of life spent in good health, producing a widening healthspan–lifespan gap that now approaches a decade globally and exceeds 12 years in the United States. Conceptual approaches for aging intervention range from largely mechanistic-based frameworks, such as the hallmarks of aging, to more function-first approaches like the World Health Organization’s intrinsic capacity model. Because biological aging is driven not by a single mechanism, but by a network of interacting hallmarks, and because many aspects of physical and cognitive function can be declining together leading up to the time period spent in the healthspan–lifespan gap, interventions that target only one process or area of function are unlikely to compress this gap substantially. This perspective makes the translational case for combining – and deliberately sequencing – potentially complementary categories of intervention: senolytics that clear senescent cells, regenerative support that supports stem cell function, joint support to enhance mobility, and nicotinamide adenine dinucleotide (NAD+) repletion that supports cellular energetics. The rationale rests on documented cross-talk among these mechanisms: as an example, senescent cells consume NAD+ and impair the niches in which stem cells operate, so clearing senescent burden plausibly creates a more permissive environment for both NAD+ restoration and regenerative signaling. A recently published preclinical study demonstrated synergistic healthspan and lifespan extension when a senolytic immunotherapy was combined with personalized mesenchymal stem cells in accelerated-aging models, providing proof of concept for the combination principle. A 12-week pilot trial using newer generation methylation clocks (e.g., DunedinPACE, OMICmAge) is planned to test an integrated nutraceutical and botanical protocol directly.

An Integrative Interim Safety Overview of Two Open Label Studies with BM-MSCs

Darius Bain — 2026-10-15

StromaForte is an allogeneic bone marrow-derived mesenchymal stromal cell (BM-MSC) investigational medicinal product under evaluation in two ongoing open-label clinical studies in The Bahamas. One study evaluates systemic administration in participants enrolled for cardiovascular-event prevention, and the second evaluates local and/or systemic administration in participants with musculoskeletal injury or degeneration.

This manuscript summarizes an integrated interim safety analysis with a data cut-off of 10 March 2026. The safety population included all treated participants. Adverse events, serious adverse events, deaths, laboratory abnormalities reported as adverse events, vital signs, and supportive follow-up-time adjusted incidence rates were summarized descriptively.

The pooled safety population comprised 305 treated participants, contributing 329 patient-years of follow-up. Overall, 162 participants (53.1%) reported at least one adverse event, and 119 (39.0%) reported at least one treatment-related adverse event. Events were predominantly non-serious and were most often recorded under MedDRA System Organ Class (SOC) Investigations, largely reflecting protocol-defined clinically significant blood pressure or laboratory findings. Six participants (2.0%) experienced a serious adverse event; none were assessed as related to the study treatment. One death due to pancreatic carcinoma occurred 585 days after treatment and was assessed as unrelated. No adverse events leading to treatment discontinuation or dose modification were reported. No new safety signal, urgent safety measure, or safety-driven change to reference safety information was identified.

Based on available interim data, StromaForte demonstrated an acceptable and manageable safety profile in the studied populations and administration settings. Interpretation remains provisional because both studies are ongoing, follow-up is incomplete, laboratory follow-up is sparse, and repeated-dose experience remains limited.

Democratizing the Science of Wellness: Leveraging Real-World Personal Data and Decentralized Infrastructure to Accelerate Longevity and Regenerative Medicine

Noah Craft — 2026-10-15

Traditional clinical trial infrastructure is fundamentally bottlenecked by high costs, rigid protocols, and an over-reliance on centralized clinical settings. These limitations disproportionately impact the fields of health longevity, alternative medicine, nutraceuticals, and regenerative therapies, where interventions are highly personalized and real-world efficacy often diverges from idealized laboratory settings. This paper outlines a paradigm shift toward a decentralized, participatory research model, termed “The Science of You”. Utilizing the Consumer Health, Learning, and Organizing Ecosystem (CHLOE) infrastructure developed by People Science, we demonstrate how rigorous, Institutional Review Board (IRB)-approved, virtual and decentralized clinical trials (DCTs) can empower individuals to test interventions on their unique physiological profiles. By bridging the gap between consumer curiosity and clinical-grade evidence, this model accelerates translational science, reduces research costs, and builds a comprehensive, decentralized repository of real-world personal data. We review recent validation studies utilizing this infrastructure, including remote clinical trials on fasting mimetics and GABA-producing probiotics, to illustrate how structured, participant-led data collection can unlock scalable, ethical, and highly accessible paths toward healthy longevity.

XoGlo® Pro, Placental MSC-Derived Exosomes: Moving Towards Longevity

Dillon Betancourt — 2026-10-15

Regenerative medicine requires scalable, well-characterized biologic platforms that support tissue repair and immune modulation while meeting standards for quality, safety, reproducible manufacturing, and ethical clinical development. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs), including small EVs and exosome-enriched preparations, are being investigated as cell-free biologics because they transfer regulatory proteins, lipids, metabolites, and nucleic acids to recipient cells. This translational study evaluated XoGlo^® Pro, a placental MSC-derived EV preparation, using multimodal analytical characterization, dermal repair-relevant in vitro assays, observational clinical case materials, and a small open-label proof-of-concept clinical study $(n = 5)$ in adults with healthy longevity-related functional concerns. Participants received a single 15 ml intravenous administration of XoGlo^® Pro (1 mg ml^-1 total protein; 15 mg total protein) and were followed for 1 month for safety and exploratory changes in function, fatigue, mood, cognition, and physical performance. No serious adverse events were observed. XoGlo^® Pro was produced from human placental MSCs under serum-free conditions and characterized by nanoparticle tracking analysis, transmission electron microscopy, dSTORM imaging, and immunoblotting. Functional assays assessed fibroblast wound closure, phenotype-associated marker expression, viability, proliferation, collagen-associated deposition, and macrophage cytokine responses following lipopolysaccharide stimulation. XoGlo^® Pro demonstrated a small-EV-enriched analytical profile with EV-associated markers. In vitro, XoGlo^® Pro enhanced fibroblast gap closure, viability, proliferation, phenotype-associated modulation, collagen-associated deposition, and attenuated inflammatory macrophage cytokine secretion. De-identified clinical images provided observational context for dermatologic and wound-repair applications. In the proof-of-concept cohort, directional improvements were observed across selected functional, fatigue, mood, cognitive, and performance measures. These findings are exploratory and hypothesis-generating and support further controlled investigation of XoGlo^® Pro in tissue repair, immune modulation, healthy longevity, and functional resilience.

Age-Reversal

William Faloon — 2026-10-15

This perspective discusses emerging regenerative interventions that target biological aging. Over recent decades, scientific advances have expanded understanding of aging as a potentially modifiable biological process. Technologies under investigation include partial cellular reprogramming, senescent cell clearance, artificial-intelligence-driven drug discovery, organ regeneration, and modulation of epigenetic aging clocks.

Preclinical studies indicate that aged cells may regain more youthful functional characteristics under specific experimental conditions. For example, inhibition of interleukin-11 signaling initiated in late life extended median lifespan by approximately 20–25% in mice and partial reprogramming has improved tissue function and survival in aged mouse model. Developments in DNA-methylation-based biomarkers now permit estimation of biological age, allowing more efficient assessment of candidate interventions. All reprogramming data to date are preclinical, and human senolytic and IL-11 data are early-phase.

Although many findings remain experimental or early translational, they represent a convergence of approaches that may influence future biomedical research. This paper summarizes selected topics related to biological age modulation and highlights ongoing areas of investigation.